



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

11<sup>th</sup> December 2024

To,  
**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5th Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Sub: Clarification for Financial results - GLAXO**

This is with reference to your email dated 4<sup>th</sup> December 2024 seeking clarification for financial results submitted for quarter & half year ended 30<sup>th</sup> September 2024. While we have submitted detailed cash flows in the annual financials statement every year, in the half yearly results, we have submitted condensed cash flow information on the basis of below guidance:

As per Regulation 33(b) of SEBI (Listing Obligations and disclosure Requirements Requirements) Regulations, 2015, "the quarterly and year to date results shall be prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 or Indian Accounting Standard 34 (AS 25/ Ind AS 34 - Interim Financial Reporting), as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder, or as specified by the Institute of Chartered Accountants of India, whichever is applicable."

As per para 8 of Ind AS 34, an Interim financial report shall include, at a minimum, the following components:

1. a condensed balance sheet;
2. a condensed statement of profit and loss;
3. a condensed statement of changes in equity;
4. **a condensed statement of cash flows; and**
5. selected explanatory notes.

As per para 10 of Ind AS-34, if entity publishes a set of condensed financial statements in its interim financial report, those condensed statements shall include, at a minimum, **each of headings and subtotals that were included in its most recent annual financial statements** and the selected explanatory notes as required by this Standard. Additional line items or notes shall be included if their omission would make the condensed interim financial statements misleading".

Accordingly, in the half year results as on 30<sup>th</sup> September 2024, we have included the headings and subtotals as that was presented in the most recent annual financial statement i.e. 31<sup>st</sup> March 2024.

Additionally, the requisite reporting with all particulars in the prescribed format in XBRL form has been uploaded within the due date for the period ended September 30, 2024.

In Annexure 1 of this response, we are pleased to share the cash flow statement for the period ended September 30, 2024, in the same format we presented in the annual financial statement.

Going forward, in the next half year results, we will include the detailed cash flow statement as we present in the annual financial statements.

The Limited Review Report for the quarter and six months ended September 30, 2024 was digitally signed by the Statutory Auditors post approval of the results by the Board of Directors in their meeting held on October, 29, 2024. However, while merging the pages of the Limited Review Report and the Limited Review Results for uploading on the stock exchange, the DSC did not appear in the merged document while uploading. On being aware of the error, we tried re-uploading the documents. However, we could not do so in 'Quick Results' as the site didn't allow to re-upload. Hence, the same were uploaded in the General Updates immediately on NEAPS. Attached is the screenshot of the same. We have also attached herewith the signed document uploaded.

Kindly take submission on records.

Thanking you,

Yours faithfully,  
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President - Administration, Real Estate  
& Company Secretary